Clinical trials & evidence

AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?

Beans for men, broccoli for women? The real cardiometabolic warning is that risk starts by 22

Radioligand Therapy Is Building Its Evidence Base. Now Build the Infrastructure.

Tau Is Back. Certainty Is Not.

Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing

Desmoid Tumours Are Not Benign to the People Living With Them

Pancreatic Cancer Is Forcing Regulators to Move Faster

When Dementia Takes Speech, Trials Must Catch Up

Treating hypertension in pregnancy is possible. Making it routine care is the policy challenge
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
